Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework

Clin Neurol Neurosurg. 2024 Jan:236:108071. doi: 10.1016/j.clineuro.2023.108071. Epub 2023 Nov 28.

Abstract

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases among the older population. Its main pathological features include the abnormal deposition of extracellular amyloid-β plaques and the intracellular neurofibrillary tangles of tau proteins. Its clinical presentation is complex. This review introduces the pathological processes in AD and other common neurodegenerative diseases. It then discusses the positron emission tomography (PET) probes that target amyloid-β plaques and tau proteins for diagnosing AD. According to the A/T(N) research framework, combined targeted amyloid-β and tau protein detection via PET to further improve the diagnostic accuracy of AD. In particular, the properties of the 18F-flortaucipir and 18F-MK6240 tracers-may be more beneficial in helping to differentiate AD from other common neurodegenerative diseases, such as dementia with Lewy bodies, Parkinson's disease dementia, and frontotemporal dementia. Furthermore, the A/T(N) research framework should be used as the clinical diagnosis model of AD in the future.

Keywords: Alzheimer’s disease; Aβ; Identification; Positron emission tomography; Tau protein.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / diagnostic imaging
  • Amyloid beta-Peptides / metabolism
  • Diagnosis, Differential
  • Frontotemporal Dementia*
  • Humans
  • Neurodegenerative Diseases*
  • Parkinson Disease* / pathology
  • Positron-Emission Tomography / methods
  • tau Proteins

Substances

  • tau Proteins
  • Amyloid beta-Peptides